First safety check for new ADPKD drug candidate
NCT ID NCT07022119
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This early-stage study tested the safety and how the body handles VX-407 in 32 healthy adults. Participants received either the drug or a placebo to check for side effects and measure drug levels in the blood. The results will help decide if VX-407 should move into future trials for people with autosomal dominant polycystic kidney disease (ADPKD).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON Lenexa
Lenexa, Kansas, 66219, United States
Conditions
Explore the condition pages connected to this study.